The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Open accessAbstract
Efficacy of antiangiogenic immunotherapy is associated with intratumoral formation of high endothelial venules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the multiple preclinical studies, angiogenesis inhibitor enhanced the efficacy of α-PD-1/PD-L1 in murine tumor models [106–108].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [108]
In the citing paper
“These findings suggest that the superior therapeutic response achieved with VEGFA-targeting agents plus PD-L1 inhibitors may involve an unsuspected vascular component”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Allen et al., 2017
In the citing paper
“over time, tumours again become hypoxic and escape from this combined treatment approach via upregulation of PD-L1 on tumour cells and stromal cells of the TME, including ECs and immune cells98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
In the citing paper
“The combination of anti-VEGFR2 and anti-PD-L1 antibodies, however, did not improve survival in a glioblastoma model98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
In the citing paper
“upregulation of PD-L1 has been demonstrated on both ECs and tumour cells following treatment with anti-VEGFR2 therapy98.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [98]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“INTRODUCTION Sustained angiogenesis and immunosuppression are hallmarks of cancer (1).”
BackgroundSelf-citationPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“In addition, sufficient T cell infiltration in human tumors appeared to be a rate-limiting step for responses to PD-L1 blockade (33, 53).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“In line with this concept, antiangiogenic therapy normalizes tumor blood vessels, albeit transiently, resulting in better blood and oxygen flow and possibly alsomore efficient T cell extravasation from the blood into the tumor (56, 57).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“Retrospective clinical studies have shown correlations between tumor PD-L1 expression and response to PD-1/ PD-L1 checkpoint blockade therapy (51, 52).”
BackgroundInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 1×
“This is based on the observation that cell constituents of tumors can express various surface molecules (such as PD-L1) that engage receptors (such as PD-1) on the surfaces of activated T cells, causing T cell anergy or exhaustion (6, 7).”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Self-citationNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“In line with this concept, antiangiogenic therapy normalizes tumor blood vessels, albeit transiently, resulting in better blood and oxygen flow and possibly alsomore efficient T cell extravasation from the blood into the tumor (56, 57).”
BackgroundNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · cited 1×
“Thus, we can evaluate true response and relapse phases in a single model (17, 19, 26).”
MethodSelf-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“Notwithstanding the favorable effects of these inhibitors in some patients, they improve progression-free survival and quality of life, but are unfortunately short-lived and modestly influence overall survival in most patients (12, 15, 16).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Self-citationTumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationGabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 1×
“VEGFalso directly inhibits dendritic cell (DC)maturation and activates antigen-specific regulatory T cells in a neuropilin-1–dependent manner (10, 11).”
BackgroundTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030 · cited 1×
“Notwithstanding the favorable effects of these inhibitors in some patients, they improve progression-free survival and quality of life, but are unfortunately short-lived and modestly influence overall survival in most patients (12, 15, 16).”
BackgroundAbnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738 · cited 1×
“Notwithstanding the favorable effects of these inhibitors in some patients, they improve progression-free survival and quality of life, but are unfortunately short-lived and modestly influence overall survival in most patients (12, 15, 16).”
BackgroundHEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713 · cited 2×
“With regard to the underlyingmechanisms of HEV induction in tumors, what is currently known is that CD11c DCs appear to be essential for the maintenance of HEVs in lymphoid organs (39).”
BackgroundPrognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661 · cited 1×
“Consequently, tumor-infiltrating T cells are generally absent or sparse in tumors; however, their presence is prognostic and predictive of response to standard therapies in many tumor types (54, 55).”
BackgroundDeciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598 · cited 3×
“Tumor angiogenic vasculature thwarts the extravasation of tumor-reactive T cells and fosters an immunosuppressive microenvironment that allows tumors to evade host immunosurveillance (8).”
BackgroundSchmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 1×
“(48), we describe the up-regulation of PD-L1, the ligand of the negative checkpoint regulator PD-1 found on T cells, as an adaptive immunosuppressive mechanism that limited the efficacy of antiangiogenic agents.”
BackgroundDendritic cells and cytokines in human inflammatory and autoimmune diseases
BLANCO, P., PALUCKA, A., PASCUAL, V, & BANCHEREAU, J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.004 · Cited by 566
Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice
Friedmann-Morvinski, D., Bushong, E. A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M. H., & Verma, I. M. (2012) · Science · doi:10.1126/science.1226929 · Cited by 562 · cited 1×
“Verma at Salk Institute), generated from embryonic C57B/L6 neural stem cells infected with shP53-shNF1 and shPTENcontaining lentiviral vectors (70), were implanted intracranially into the striatum of 7- to 9- week-old female and male syngeneic C57BL/6 mice.”
MethodVEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Self-citationMartinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.-J., Rochaix, P., & Girard, J.-P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 516 · cited 1×
“Recent studies have discovered that various human cancers can spontaneously develop areas of HEVs and that their presence correlates with reduced tumor size and improved patient outcome (58, 59).”
BackgroundThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481 · cited 3×
“There is accumulating evidence that these two phenotypes are interconnected and facilitated by shared regulators not only during normal physiological processes, but also in cancer (2).”
BackgroundInfluentialFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472 · cited 4×
“In addition, sufficient T cell infiltration in human tumors appeared to be a rate-limiting step for responses to PD-L1 blockade (33, 53).”
BackgroundResultInfluentialTargeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 469
Rennert, P. D., Browning, J. L., Mebius, R., Mackay, F., & Hochman, P. S. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1999 · Cited by 388
Hui, E. P., Chan, A. T. �., Pezzella, F., Turley, H., To, K., Poon, T. C. W., Zee, B. C.-Y., Mo, F. K. F., Teo, P. M. L., Huang, D. P., et al. (2002) · PubMed · Cited by 333
Dirkx, A. E. M., Egbrink, M. G. A. O., Kuijpers, M. J. E., van der Niet, S. T., Heijnen, V. V. T., Steege, J. C. A. B.-T., Wagstaff, J., & Griffioen, A. W. (2003) · PubMed · Cited by 325
Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules
Moussion, C., & Girard, J.-P. (2011) · Nature · doi:10.1038/nature10540 · Cited by 311 · cited 1×
“Ablation of DCs, pharmacological inhibition, or genetic deletion of LTbR in ECs is sufficient to impair formation of HEVs in lymphoid organs (43, 60, 61).”
BackgroundBrowning, J. L., Allaire, N., Ngam-ek, A., Notidis, E., Hunt, J., Perrin, S., & Fava, R. A. (2005) · Immunity · doi:10.1016/j.immuni.2005.10.002 · Cited by 265
INTERFEROME: the database of interferon regulated genes
Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 265 · cited 1×
“We then investigated the expression profile of three well-known IFNg-inducible genes: the chemokine Cxcl10,Mx1 (interferon-induced guanosine 5′-triphosphate–binding protein MX1), and Ifit3 (interferoninduced protein with tetratricopeptide repeats) (32).”
BackgroundRole of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247 · cited 1×
“Thus, we can evaluate true response and relapse phases in a single model (17, 19, 26).”
MethodOtt, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230 · cited 1×
“PD-L1 expression can be induced by hypoxia via hypoxiainducible factor 1 and by interferon-g (IFNg) (29, 30).”
BackgroundAllen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221
Self-citationLiu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193 · cited 1×
“Recent studies have discovered that various human cancers can spontaneously develop areas of HEVs and that their presence correlates with reduced tumor size and improved patient outcome (58, 59).”
What brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320087 · Cited by 175
Lee, M., Kiefel, H., LaJevic, M. D., Macauley, M. S., Kawashima, H., O’Hara, E., Pan, J., Paulson, J. C., & Butcher, E. C. (2014) · Nature Immunology · doi:10.1038/ni.2983 · Cited by 166
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 151 · cited 8×
“The negative feedback loop, entailing the interaction of adaptive ICs with PD-L1 tumor and host cells, is in line with our former observation (17) that the efficacy of VEGF/VEGFR inhibitors depended on forming an immunostimulatory environment, in part by converting innate ICs to an angiostatic and immunostimulatory ph…”
BackgroundMethodResultInfluentialSelf-citationLymphotoxin signalling in immune homeostasis and the control of microorganisms
Upadhyay, V., & Fu, Y. (2013) · Nature reviews. Immunology · doi:10.1038/nri3406 · Cited by 151
Jiménez-Valerio, G., Martínez‐Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suárez, C., del Muro, X. G., Carles, J., Viñals, F., Graupera, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.015 · Cited by 129
Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
Lukashev, M., LePage, D., Wilson, C. A., Bailly, V., Garber, E. A., Lukashin, A., Ngam-ek, A., Zeng, W., Allaire, N., Perrin, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0217 · Cited by 125
Understanding high endothelial venules: Lessons for cancer immunology
Ager, A., & May, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008791 · Cited by 114
Kandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 99 · cited 2×
“The tumor vasculature is a major barrier for lymphocytes because it also up-regulates PD-L1 and down-regulates the lymphocyte adhesion molecules ICAM-1 and VCAM-1 that together hinder T cell activation and infiltration into the tumor (9, 11).”
BackgroundOnrust, S. V., Hartl, P. M., Rosen, S. D., & Hanahan, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118406 · Cited by 99
Self-citationWu, X., Giobbie‐Hurder, A., Liao, X., Lawrence, D. P., McDermott, D. F., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0084 · Cited by 94 · cited 1×
“These favorable outcomes were associated with increased expression of the adhesion molecules ICAM-1 and VCAM-1 in ECs and lymphocyte infiltration (68).”
BackgroundIntratumoral LIGHT Restores Pericyte Contractile Properties and Vessel Integrity
Johansson, A., Li, Z., Lakhiani, D. D., He, B., Wang, X., Hamzah, J., & Ganß, R. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.004 · Cited by 91 · cited 1×
“Recently, intratumoral delivery of a LIGHT peptide was able to normalize tumor vessels and improve tumor perfusion by reestablishing tight pericytevessel alignment (63).”
BackgroundInduction of CD4+Regulatory and Polarized Effector/helper T Cells by Dendritic Cells
Lutz, M. B. (2016) · Immune Network · doi:10.4110/in.2016.16.1.13 · Cited by 65
The Cytoplasmic Domain of the Lymphotoxin-β Receptor Mediates Cell Death in HeLa Cells
Wu, M., Wang, P.-Y., Han, S., & Hsieh, S.-L. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11868 · Cited by 45
Promising Early Results for Immunotherapy-Antiangiogenesis Combination
Garber, K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju392 · Cited by 37
Norris, P. S., & Ware, C. F. (2007) · Springer eBooks · doi:10.1007/978-0-387-70630-6_13 · Cited by 33
Martinet, L., & Girard, J. (2013) · OncoImmunology · doi:10.4161/onci.26470 · Cited by 24
Anti-angiogenesis immunotherapy
Schoenfeld, J. D., & Dranoff, G. (2011) · Human Vaccines · doi:10.4161/hv.7.9.16407 · Cited by 21
Tight control – decision-making during T cell–vascular endothelial cell interaction
Firner, S., Onder, L., Nindl, V., & Ludewig, B. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00279 · Cited by 17 · cited 1×
“Ablation of DCs, pharmacological inhibition, or genetic deletion of LTbR in ECs is sufficient to impair formation of HEVs in lymphoid organs (43, 60, 61).”
Background
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Recent preclinical studies have also shown that antiVEGF therapy can improve anti-PD-L1 (programmed deathligand 1) treatment, specifically when it generates intratumoral high endothelial venules (HEVs) that facilitate enhanced cytotoxic T lymphocyte (CTL) infiltration and tumor cell destruction (Allen et al., 2017).”
BackgroundEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Metadata
- Authors
- Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., & Bergers, G.
- Affiliations
- VIB-KU Leuven Center for Cancer Biology (BE)
- University of California, San Francisco (US)
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Allen, Elizabeth
- Jabouille, Arnaud
- Bergers, Gabriele
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-04-12
- Volume
- 9
- Issue
- 385
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5554432
- OpenAlex
- W2605792367
- Cited by
- 820
- References
- 71
- Citations by year
- 2026: 78 · 2025: 92 · 2024: 87 · 2023: 103 · 2022: 113 · 2021: 109 · 2020: 89 · 2019: 70 · 2018: 55 · 2017: 24
- FWCI
- 28.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Funders
- NIH (U54CA163155, R01CA188404, RO1CA20153)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-angiogenic therapy, PD-L1 blockade, high endothelial venules, VEGFR-2 inhibition, PD-L1, antitumor immunity, interferon-gamma, PD-1/PD-L1 immune checkpoint, cytotoxic T lymphocytes, lymphocyte infiltration, glioblastoma, pancreatic neuroendocrine tumors, breast cancer, combination immunotherapy, tumor vasculature
- MeSH terms
- Animals, Breast Neoplasms, Female, Interferon-gamma, Mice, Inbred C57BL, Neoplasm Recurrence, Local, Pancreatic Neoplasms, T-Lymphocytes, Cytotoxic, Signal Transduction, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.